Hong Kong
· Delayed Price · Currency is HKD Shenzhen Hepalink Pharmaceutical Group Company Description
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. engages in the manufacture and sale of pharmaceutical products in Hong Kong, the United States, Europe, Mainland China, and internationally.
The company operates through four segments: Finished Dose Pharmaceutical Products, Active Pharmaceutical Ingredients (API), Contract Development and Manufacturing Organization, and Others.
Its pharmaceutical products consist of finished dose pharmaceutical products, which primarily include enoxaparin sodium injection; API products, including heparin sodium API and enoxaparin sodium API; and other products, such as pancreatin API.
The company is also involved in the provision of research and development, manufacturing, quality management, and program management services; and development and manufacture of recombinant pharmaceutical products, critical non-viral vectors, intermediates for gene therapy, and naturally derived pharmaceutical products.
In addition, it engages in research, development, production, services, and trading biopharmaceutical; property management, investment management and consulting, biopharmaceutical technology development and consulting, and equity and venture investment activities; production and sale of heparin sodium; provision of services on pharmaceutical related activities; and trading of medical and biopharmaceutical products.
The company was formerly known as Shenzhen Hepalink Pharmaceutical Co.,Ltd. and changed its name to Shenzhen Hepalink Pharmaceutical Group Co., Ltd. in February 2017.
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. was founded in 1998 and is headquartered in Shenzhen, the People’s Republic of China.
| Country | China |
| Founded | 1998 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 2,080 |
| CEO | Yu Shan |
Contact Details
Address: No. 21 Langshan Road Shenzhen, 518057 China | |
| Phone | 86 755 2698 0200 |
| Website | hepalink.com |
Stock Details
| Ticker Symbol | 9989 |
| Exchange | Hong Kong Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CNY |
| ISIN Number | CNE100003YN2 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Li Li | Co-Founder, Chairman of the Board and President |
| Yu Shan | Co-Founder, GM, Group Vice President and Executive Director |
| Juan Chen | Vice President of Finance, Chief Financial Officer and Financial Controller |
| Tan Li | Vice President, Deputy GM and Director |
| Fengqi Qian | Company Secretary |
| Tao Han M.B.A. | Chief Business Officer |
| Xi Gao | Senior Vice President of Global Supply Chain |